NanoViricides, Inc.
135 Wood Street
Suite 205
West Haven,
CT 06516
United States - Map
Phone: 203-937-6137
Fax: 281-581-2260
Web Site: http://www.nanoviricides.com
| NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus (HCV), Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The companys products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide against rabies; and HCV, a Hepatitis C nanoviricide. It also provides HivCide-I, a drug project against HIV-I; HivCide-II, a targeted nanoviricide against HIV strains; and EKCCide-I, a nanoviricide drug, which indicates efficacy and safety of a drug candidate against the severe pink eye disease caused by adenoviruses called epidemic kerato-conjunctivitis. NanoViricides, Inc. has a pre-clinical study agreement with Thevac, LLC for the evaluation of the companys universal anti-influenza drug candidate FluCide. The company was founded in 2005 and is headquartered in West Haven, Connecticut. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Anil R. Diwan Ph.D., 50
Chairman and Pres |
$
252.00K | N/A | Dr. Eugene Seymour MD, MPH, 68
Chief Exec. Officer, Chief Financial Officer, Principal Accounting Officer |
$
250.00K | N/A | Dr. Krishna Menon RCM, Ph.D., VMD, 63
Chief Regulatory Officer and Member of Scientific Advisory Board |
N/A
| N/A | Dr. Randy Barton Ph.d., 62
Chief Scientific Officer |
N/A
| N/A | Dr. Jayant Tatake ,
VP of R&D |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
